Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
Tadesse M AbegazVakaramoko DiabyFatimah SherbenyAskal Ayalew AliPublished in: Clinical drug investigation (2022)
Dapagliflozin added to the standard of care was cost effective relative to the standard of care alone in the USA for patients with diabetic nephropathy.